SAP Cloud ERP for Pharma & Life Science: A smarter ERP starting point for R&D-driven companies
How Cloud Express helps biotech and life sciences companies scale faster, improve controls, and prepare for growth
Introduction
The companies most likely to outgrow their IT or ERP systems are often the ones least prepared to replace them. In pharma and life sciences, that is not just an IT problem, it can quickly become a compliance, auditability, investor confidence, and growth problem.
R&D-driven pharma and life sciences companies including biotech and early-commercialisation organisations are under increasing pressure to operate with the discipline of larger enterprises, but without the same IT budgets, implementation experience or internal transformation capacity. Many still rely on spreadsheets, manual controls and disconnected systems that work in the early stages of operating a company but become difficult to sustain as the business grows.
This is where SAP Cloud ERP for pharma, delivered through Cloud Express, can provide a practical starting point. What sets Cloud Express apart from other SAP accelerators is the combination of pre-configured, industry-tailored templates with PwC's Activate+ delivery methodology — adding rigour, innovation and adoption discipline on top of standard project delivery methodologies to compress timelines and reduce risk without compromising quality and value. It is also AI-powered by design, embedding SAP Business AI, Joule and SAP Business Data Cloud into a future-ready core, rather than treating AI as an add-on.
Cloud Express is PwC's accelerated SAP Cloud ERP offering, designed to help biotech and life sciences companies build a fast, cost-effective, scalable and credible ERP backbone for organisations focused on R&D and early commercialisation rather than large, complex GxP manufacturing landscapes.
The Pharma and Life Sciences ERP challenge
Pharma and life sciences is one of the most regulated industries in the world. Organisations must manage system validation, traceability, change control, audit trails and compliance requirements from regulators such as the FDA and EMA. These requirements make ERP transformation more demanding in Pharma than in many other sectors - which is why the starting point matters.
Five reasons it works for R&D-driven companies
- Speed to value. R&D-focused organisations need to preserve capital for science, clinical development and product progress. Cloud Express enables implementation of an IT / ERP backbone in weeks rather than months, helping organisations avoid long, costly transformation programs while still improving operational discipline.
- Cost efficiency. Investor-backed companies need to justify every major investment. Cloud Express offers predictable cost, transparent pricing and a lean implementation footprint. It is important because investors typically want capital directed toward research.
- Scalability and modularity. Companies can begin with core finance and procurement capabilities, then add supply chain, HR, tax or other functions as their operating model matures. This modularity supports the journey from R&D to early commercialization.
- Professionalization of controls. Moving from spreadsheets and manual controls to automated ERP-based controls strengthens auditability, compliance discipline and operational maturity, especially important in regulated environments where evidence, traceability and control reliability matter. And relevant for transparency for investors and business partners.
- Investor and acquisition readiness. Most large pharma companies run SAP. A biotech or early-stage pharma company with a professional SAP ERP backbone is better positioned for due diligence, acquisition or integration into a larger enterprise — supporting smoother deals and stronger long-term valuation.
Where Cloud Express fits in Pharma and Life Science industries
Cloud Express is particularly suitable for:
- R&D-driven pharma and biotech companies
- Early-commercialization organizations
- Investor-backed and PE-backed companies
- Carve-outs and subsidiaries of larger pharma groups
- Organizations preparing for acquisition or integration into larger pharma environments
For the most complex, fully integrated GxP manufacturing landscapes, a phased approach still makes sense - start with the core, then expand as SAP's public cloud capabilities mature over the next years. In pharma, credibility comes from being precise: Cloud Express is a practical, scalable ERP foundation for organizations that need professional controls, faster implementation and the ability to grow over time.
A three-phase framework
Cloud Express should not be treated as a "big bang" transformation. For biotech and life sciences companies, the stronger approach is a phased model.
Phase 1 — Establish the professional core. Create a reliable ERP backbone within months for the functions that need discipline and visibility: finance, procurement, sales, basic supply chain, tax and HR. The real value isn't go-live, it's replacing fragmented manual processes with standardized, auditable workflows. For investor-backed companies, this matters because investors don't only evaluate scientific potential; they also assess whether the business can scale responsibly.
Phase 2 — Connect the regulated ecosystem. After initial ERP stabilization. Connect the systems that support regulated pharma operations — LIMS, MES, Quality Management Systems and other GxP-specific applications via SAP Business AI Platform. The critical decision is which processes should sit inside the ERP, and which should remain in specialist systems. Trying to force every GxP process into the ERP core too early can reduce flexibility and increase complexity. The better approach: keep the ERP core clean while integrating specialist systems where needed.
Phase 3 — Scale with the SAP roadmap. Ongoing. As the business grows, the ERP foundation should evolve with it, particularly for biotech companies moving from research into clinical development, early commercialization, manufacturing partnerships or acquisition. SAP's public cloud capability for pharma is evolving rapidly, and organizations should monitor the roadmap closely. The advantage of this phased approach: companies don't have to build everything at once. They can create a professional foundation now and expand as both the business and SAP's industry capabilities mature.
The cost of standing still
For R&D-focused organizations, the question is no longer "Which ERP should we implement?" The better question is: How do we build a professional ERP foundation without over-engineering before we're ready? The cost of inaction shows up as:
- Manual financial processes and spreadsheet-based controls
- Limited auditability and weak visibility across finance, tax, HR and operations
- Disconnected procurement and supply chain
- Difficulty integrating with regulated systems
- Reduced investor confidence in operational maturity
These aren't just operational inefficiencies. They affect due diligence, valuation and the ability to scale responsibly.
Conclusion
The future of pharma will be defined by speed, innovation and trust. R&D-driven life sciences businesses need to move quickly, but they also need operational maturity to satisfy investors, auditors, regulators, business partners and potential future investors.
For smaller pharma, biotech, R&D-focused, investor-backed and early-commercialization companies, Cloud Express offers a practical way to build a professional SAP Cloud ERP backbone without overbuilding too early. The organizations that act early can create stronger controls, improve auditability, support growth and prepare for future integration into larger pharma ecosystems.
Ready to explore Cloud Express for your organization?
PwC can help assess your current operating model, identify the right starting point and build a transformation path tailored to your organisation’s growth stage, regulatory requirements and future ambitions. And while this blog focuses on pharma and life sciences, Cloud Express is not limited to one industry. If you operate in another sector, PwC and SAP can help assess whether it is the right fit for your business needs and growth ambitions.
About the Author
